Literature DB >> 29080909

Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications.

Matthieu Legrand1,2,3,4, Pierre-Olivier Ludes5,6, Ziad Massy7,8, Patrick Rossignol9, Jiri Parenica10,11, Jin-Joo Park12, Shiro Ishihara13, Khalid F AlHabib14, Aldo Maggioni15, Òscar Miró16, Naoki Sato13, Alain Cohen-Solal17, Enrique Fairman18, Johan Lassus19, Veli-Pekka Harjola19, Christian Mueller20, Franck W Peacock21, Dong-Ju Choi12, Patrick Plaisance22, Jindřich Spinar10,11, Mikhail Kosiborod23, Alexandre Mebazaa5,6,24,25, Etienne Gayat5,6,24,25.   

Abstract

BACKGROUND: The interaction between chronic medications on admission and the association between serum potassium level and outcome in patients with acute heart failure (AHF) are unknown.
METHODS: Observational intercontinental study of patients admitted with AHF. 15954 patients were included from 12 cohorts in 4 continents. Main outcome was 90-day mortality. Clinical presentation (medication use, hemodynamics, comorbidities), demographic, echocardiographic, and biochemical data on admission were recorded prospectively in each cohort, with prospective adjudication of outcomes.
RESULTS: Positive and negative linear relationships between 90-day mortality and sK+ above 4.5 mmol/L (hyperkalemia) and below 3.5 mmol/L (hypo-kalemia) were observed. Hazard ratio for death was 1.46 [1.34-1.58] for hyperkalemia and 1.22 [1.06-1.40] for hypokalemia. In a fully adjusted model, only hyperkalemia remained associated with mortality (HR 1.03 [1.02-1.04] for each 0.1 mmol/l change of sK+ above 4.5 mmol/L). Interaction tests revealed that the association between hyperkalemia and outcome was significantly affected by chronic medications. The association between hyperkalemia and mortality was absent for patients treated with beta blockers and in those with preserved renal function.
CONCLUSIONS: In patients with AHF, sK+ > 4.5 mmol/L appears to be associated with 90-day mortality. B-blockers have potentially a protective effect in the setting of hyperkalemia.

Entities:  

Keywords:  B-blockers; Heart failure; Mortality; Potassium; Renal failure

Mesh:

Substances:

Year:  2017        PMID: 29080909     DOI: 10.1007/s00392-017-1173-3

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  26 in total

1.  Renal and extrarenal regulation of potassium.

Authors:  G Giebisch; R Krapf; C Wagner
Journal:  Kidney Int       Date:  2007-06-13       Impact factor: 10.612

2.  Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort.

Authors:  Alexandre Mebazaa; Etienne Gayat; Johan Lassus; Taly Meas; Christian Mueller; Aldo Maggioni; Frank Peacock; Jindrich Spinar; Veli-Pekka Harjola; Roland van Kimmenade; Atul Pathak; Thomas Mueller; Luigi Tavazzi; Salvatore Disomma; Marco Metra; Domingo Pascual-Figal; Said Laribi; Damien Logeart; Semir Nouira; Naoki Sato; Jiri Parenica; Nicolas Deye; Riadh Boukef; Corinne Collet; Greet Van den Berghe; Alain Cohen-Solal; James L Januzzi
Journal:  J Am Coll Cardiol       Date:  2013-01-16       Impact factor: 24.094

3.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

4.  Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study.

Authors:  Sonal Korgaonkar; Anca Tilea; Brenda W Gillespie; Margaret Kiser; George Eisele; Fredric Finkelstein; Peter Kotanko; Bertram Pitt; Rajiv Saran
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

Review 5.  When cardiac failure, kidney dysfunction, and kidney injury intersect in acute conditions: the case of cardiorenal syndrome.

Authors:  Matthieu Legrand; Alexandre Mebazaa; Claudio Ronco; James L Januzzi
Journal:  Crit Care Med       Date:  2014-09       Impact factor: 7.598

6.  Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.

Authors:  Hanna Fröhlich; Lorella Torres; Tobias Täger; Dieter Schellberg; Anna Corletto; Syed Kazmi; Kevin Goode; Morten Grundtvig; Torstein Hole; Hugo A Katus; John G F Cleland; Dan Atar; Andrew L Clark; Stefan Agewall; Lutz Frankenstein
Journal:  Clin Res Cardiol       Date:  2017-04-22       Impact factor: 5.460

7.  Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.

Authors:  João Pedro Ferreira; Nicolas Girerd; Pedro Bettencourt Medeiros; Mário Santos; Henrique Cyrne Carvalho; Paulo Bettencourt; David Kénizou; Javed Butler; Faiez Zannad; Patrick Rossignol
Journal:  Clin Res Cardiol       Date:  2015-11-28       Impact factor: 5.460

Review 8.  What is the optimal serum potassium level in cardiovascular patients?

Authors:  John E Macdonald; Allan D Struthers
Journal:  J Am Coll Cardiol       Date:  2004-01-21       Impact factor: 24.094

9.  Use of aldosterone antagonists in heart failure.

Authors:  Nancy M Albert; Clyde W Yancy; Li Liang; Xin Zhao; Adrian F Hernandez; Eric D Peterson; Christopher P Cannon; Gregg C Fonarow
Journal:  JAMA       Date:  2009-10-21       Impact factor: 56.272

10.  Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).

Authors:  Romain Eschalier; John J V McMurray; Karl Swedberg; Dirk J van Veldhuisen; Henry Krum; Stuart J Pocock; Harry Shi; John Vincent; Patrick Rossignol; Faiez Zannad; Bertram Pitt
Journal:  J Am Coll Cardiol       Date:  2013-06-27       Impact factor: 24.094

View more
  11 in total

1.  Diagnostic and prognostic value of plasma volume status at emergency department admission in dyspneic patients: results from the PARADISE cohort.

Authors:  Tahar Chouihed; Patrick Rossignol; Adrien Bassand; Kévin Duarte; Masatake Kobayashi; Déborah Jaeger; Sonia Sadoune; Aurélien Buessler; Lionel Nace; Gaetan Giacomin; Thibaut Hutter; Françoise Barbé; Sylvain Salignac; Nicolas Jay; Faiez Zannad; Nicolas Girerd
Journal:  Clin Res Cardiol       Date:  2018-10-28       Impact factor: 5.460

2.  Beta-blockers do not protect against cardiac toxicity of hyperkalemia : Response to the article by Legrand et al. 'Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications' [1].

Authors:  Christian de Tymowski; Enora Atchade; Philippe Montravers; Sophie Provenchère
Journal:  Clin Res Cardiol       Date:  2018-03-12       Impact factor: 5.460

3.  Examining the "Repletion Reflex": The Association between Serum Potassium and Outcomes in Hospitalized Patients with Heart Failure.

Authors:  Kevin F O'Sullivan; Mohammad Amin Kashef; Alexander B Knee; Alexander S Roseman; Penelope S Pekow; Mihaela S Stefan; Meng-Shiou Shieh; Quinn R Pack; Peter K Lindenauer; Tara Lagu
Journal:  J Hosp Med       Date:  2019-07-24       Impact factor: 2.960

Review 4.  Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University.

Authors:  Nikolaus Marx; Heidi Noels; Joachim Jankowski; Jürgen Floege; Danilo Fliser; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2018-05-04       Impact factor: 5.460

5.  Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data.

Authors:  Rahul Aggarwal; Haares Mirzan; Nicholas Chiu; Jackson Steinkamp
Journal:  Clin Res Cardiol       Date:  2018-02-26       Impact factor: 5.460

Review 6.  [Update on heart failure].

Authors:  J Wintrich; I Kindermann; M Böhm
Journal:  Herz       Date:  2018-06-05       Impact factor: 1.443

7.  Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK.

Authors:  Cecilia Linde; Lei Qin; Ameet Bakhai; Hans Furuland; Marc Evans; Daniel Ayoubkhani; Eirini Palaka; Hayley Bennett; Phil McEwan
Journal:  ESC Heart Fail       Date:  2019-01-10

8.  A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology.

Authors:  Patrick Rossignol
Journal:  Eur Heart J Suppl       Date:  2019-02-26       Impact factor: 1.803

9.  Characteristics, Risk Factors, and Adverse Outcomes of Hyperkalemia in Acute-on-Chronic Liver Failure Patients.

Authors:  Jun-Jun Cai; Kai Wang; Hui-Qing Jiang; Tao Han
Journal:  Biomed Res Int       Date:  2019-02-27       Impact factor: 3.411

10.  Serum potassium dynamics during acute heart failure hospitalization.

Authors:  Pedro Caravaca Perez; José R González-Juanatey; Jorge Nuche; Laura Morán Fernández; David Lora Pablos; Jesús Alvarez-García; Ramón Bascompte Claret; Manuel Martínez Selles; Rafael Vázquez García; Luis Martínez Dolz; Marta Cobo-Marcos; Domingo Pascual Figal; Maria G Crespo-Leiro; Julio Nuñez Villota; Juan Cinca Cuscullola; Juan F Delgado
Journal:  Clin Res Cardiol       Date:  2020-10-17       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.